A phase 1 study to evaluate bioequivalence between BHV-0223 40 mg Zydis® sublingual formulation and riluzole 50 mg oral tablet in healthy volunteers

Category Primary study
JournalNeurology
Year 2019
This article has no abstract
Epistemonikos ID: 061724af72eba3983b2d8c089267d933e671a40a
First added on: Feb 11, 2025